Literature DB >> 17227127

High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies.

Gladell P Paner1, Valerie Lindgren, Kris Jacobson, Kathleen Harrison, Ying Cao, Steve C Campbell, Robert C Flanigan, Maria M Picken.   

Abstract

CONTEXT: It has recently been shown by cytogenetics that there is a high incidence of chromosome 1 abnormalities in renal oncocytomas.
OBJECTIVE: To confirm the cytogenetic results by fluorescence in situ hybridization (FISH) analysis.
DESIGN: Nine additional cytogenetic analyses were added to those reported in our recent study, with a total of 27 tumors studied, which makes it the largest series of renal oncocytomas studied to date by cytogenetics and/or FISH. We used the LSI 1p36/LSI 1q25 Dual Color Probe Set to make the analyses.
RESULTS: In this study, combined cytogenetics and FISH showed loss of chromosome arm 1p1 in 48% of renal oncocytomas. By FISH, deletion of 1p36.3 was observed in 59% of renal oncocytomas, whereas by cytogenetics, abnormality in chromosome 1 was seen in 32% of tumors. However, the incidence of chromosome 1 abnormalities among 9 bilateral tumors was much higher than in single tumors (88% vs 28%, respectively). Loss of only the 1p36.3 site occurred in 2 renal oncocytomas with translocation of chromosome 1, as shown by cytogenetics. Concordance between the 2 techniques, when they were used simultaneously to detect chromosome 1p1 abnormality, was 82%.
CONCLUSIONS: This study further confirmed our prior results demonstrating the widespread occurrence of chromosome 1 abnormalities in renal oncocytomas. Although no abnormalities in chromosome 1 in tumors with normal karyotypes were detected by FISH using the current set of probes, a much higher incidence of such abnormalities was found in bilateral tumors, suggesting that genetic alterations related to the development of renal oncocytoma reside in this region.

Entities:  

Mesh:

Year:  2007        PMID: 17227127     DOI: 10.5858/2007-131-81-HIOCAI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

Review 1.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  Oncocytic mania: a review of oncocytic lesions throughout the body.

Authors:  F Guaraldi; G Zang; A P Dackiw; P Caturegli
Journal:  J Endocrinol Invest       Date:  2011-02-07       Impact factor: 4.256

3.  Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up.

Authors:  Marie Dvorakova; Rajiv Dhir; Sheldon I Bastacky; Kathleen M Cieply; Marie B Acquafondata; Carol R Sherer; Tracy L Mercuri; Anil V Parwani
Journal:  Diagn Pathol       Date:  2010-05-24       Impact factor: 2.644

4.  Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.

Authors:  Jeff A Klomp; David Petillo; Natalie M Niemi; Karl J Dykema; Jindong Chen; Ximing J Yang; Annika Sääf; Peter Zickert; Markus Aly; Ulf Bergerheim; Magnus Nordenskjöld; Sophie Gad; Sophie Giraud; Yves Denoux; Laurent Yonneau; Arnaud Méjean; Viorel Vasiliu; Stéphane Richard; Jeffrey P MacKeigan; Bin T Teh; Kyle A Furge
Journal:  BMC Med Genomics       Date:  2010-12-16       Impact factor: 3.063

5.  Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors.

Authors:  Jill M Hagenkord; Anil V Parwani; Maureen A Lyons-Weiler; Karla Alvarez; Robert Amato; Zoran Gatalica; Jose M Gonzalez-Berjon; Leif Peterson; Rajiv Dhir; Federico A Monzon
Journal:  Diagn Pathol       Date:  2008-11-06       Impact factor: 2.644

Review 6.  Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach.

Authors:  Reza Alaghehbandan; Delia Perez Montiel; Ana Silvia Luis; Ondrej Hes
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.